In the relentless landscape of metastatic breast cancer (MBC) advocacy and research, few voices carry as much weight—or as much raw, lived experience—as Dr. Kelly Shanahan, the president of METAvivor. In a recent communication to the community, Dr. Shanahan bridged the gap between personal struggle and systemic progress, offering a poignant look at the current state of MBC treatment, the critical importance of genomic vigilance, and the upcoming milestones for the organization.
The Reality of Progression: A Personal Journey
For those living with metastatic breast cancer, time is a fluid and often unforgiving metric. Dr. Shanahan, herself a patient, notes the peculiar way time accelerates in the shadow of a terminal diagnosis. Her recent personal update serves as a sobering reminder that even within the most rigorous treatment protocols, the landscape of the disease can shift with little warning.
Her summer, she candidly admits, was a "bust." The complications were two-fold: a personal injury involving her energetic eight-month-old puppy, Albus Dumbledore, and a significant setback in her clinical trial.
The clinical trial drug, which had initially shown promise in stabilizing her condition, reached a point of failure. Upon further clinical investigation, the situation was revealed to be more complex: the primary sites of her cancer that had responded to treatment remained in check, but the tumor had undergone a biological evolution. Her highly ER/PR+ MBC mutated into a low ER/PR-, HER2-low profile, demonstrating a concerning migration to the liver.
This clinical pivot necessitated an immediate recalibration of her treatment plan. After consulting with her "village of oncologists," Dr. Shanahan transitioned to a dual-pronged approach: immunotherapy, supported by findings of a high tumor mutational burden discovered via liquid biopsy, and oral chemotherapy using capecitabine (Xeloda). Early signs, such as the resolution of numbness in an area previously affected by a new metastasis, suggest the regimen may be gaining ground, though the definitive assessment remains pending upcoming scans.
The Critical Role of Biomarker Vigilance
Dr. Shanahan’s experience underscores a fundamental, often life-saving, truth in oncology: cancer is not a static entity. It is a dynamic, evolving biological process. When a patient experiences a "mixed response"—where some lesions shrink while others progress—the standard of care must adapt.
The Necessity of Re-Biopsy
A primary takeaway from Dr. Shanahan’s experience is the absolute necessity of re-biopsying new or progressive sites of disease. As tumors evolve, their receptor status (ER, PR, and HER2) can change, rendering previous treatments ineffective.
Furthermore, Dr. Shanahan emphasizes the utility of liquid biopsies. These blood-based tests allow oncologists to track circulating tumor DNA and identify new mutations as they arise. By monitoring these genetic shifts in real-time, patients and their clinical teams can make informed decisions about targeted therapies rather than relying on outdated diagnostic data.
Bridging the Knowledge Gap
To address this need, METAvivor is launching a comprehensive biomarker education program. This initiative is designed to empower patients with the knowledge to advocate for their own molecular testing. Key components of this program include:
- Digital Resources: Expanded information on the METAvivor website and social media platforms.
- Educational Panels: A dedicated session on biomarkers will take place at the Stage IV Stampede and Summit on October 5, immediately preceding the organization’s Hill Day on October 6.
- Webinar Series: A forthcoming webinar specifically addressing the challenges of managing patients with multiple, shifting biomarkers.
Strategic Partnerships and Advocacy
The advocacy ecosystem relies on the amplification of voices, and to that end, METAvivor has announced a strategic partnership with the Live from Stage 4 podcast. This collaboration is set to bring high-level, expert-led conversations to a wider audience.
The podcast serves as a vital resource, hosting leading oncologists and researchers who discuss the latest breakthroughs, the controversies surrounding current standards of care, and the practical realities of managing treatment-related side effects. Moving forward, the partnership will integrate METAvivor’s specific initiatives, including the R.I.S.E (Reach. Inform. Support. Empower) program and peer-to-peer support networks, into the podcast’s editorial calendar. By highlighting these programs, the organization hopes to provide a cohesive support structure that addresses both the physical and psychological toll of MBC.
The Mechanics of Advocacy: Grant Review and Community Engagement
Beyond treatment protocols, the heartbeat of METAvivor is its research funding. Dr. Shanahan confirmed that patient advocate reviewers are currently receiving their assigned grant applications.
This process is unique to the patient-centered model of research; by involving those who actually live with the disease in the evaluation of grant applications, METAvivor ensures that the research funded is not only scientifically rigorous but also relevant to the lived needs of the MBC community. The organization continues to call for new reviewers for the upcoming year, emphasizing that the "thoughtful input" of patients is the final, essential filter in their funding process.
Implications for the Future of MBC Care
The trajectory of Dr. Shanahan’s update points toward a future where "precision medicine" is not just a buzzword, but a daily clinical reality. The implications of this approach are profound:
- Biological Agility: Clinicians must be prepared to change treatment plans the moment a patient’s molecular profile shifts.
- Patient Autonomy: Patients who are educated about biomarkers are better equipped to challenge their care teams to perform the necessary biopsies to guide treatment.
- Holistic Support: Research funding must be coupled with psychosocial support programs like R.I.S.E to ensure that the patient is supported in every facet of their journey.
As the organization looks toward the autumn, the community’s focus shifts to the Light Up MBC event on October 13. Led by Tami Bowling and a dedicated team, this fundraiser stands as the cornerstone of METAvivor’s financial capacity to support ongoing research.
Conclusion: A Community Built on Resilience
Dr. Shanahan’s letter is a reminder that METAvivor is an organization that exists because of the community it serves. It is a grassroots movement sustained by the very people it aims to save. Whether through volunteering, fundraising, or contributing to the research review process, the strength of the organization lies in the collective action of those who refuse to let metastatic breast cancer be ignored.
As October approaches—a month that marks both crucial advocacy summits and the annual Light Up MBC fundraiser—the message from the METAvivor leadership is clear: the fight is ongoing, the science is evolving, and the need for patient-led advocacy has never been more urgent.
For those interested in participating in the upcoming Stampede or contributing to the fundraising efforts, the path forward is clearly mapped. As Dr. Shanahan continues her own treatment journey, she remains a constant, guiding voice for a community that continues to demand better, faster, and more effective answers.
Key Events Calendar:
- October 5: Stage IV Stampede and Summit
- October 6: Hill Day
- October 13: Light Up MBC Fundraiser
For more information on how to support these initiatives or to register for upcoming events, please visit the official METAvivor website.
About the Author
